<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005617" GROUP_ID="MUSKEL" ID="518304062108260062" MERGED_FROM="" MODIFIED="2008-11-12 22:20:20 +0100" MODIFIED_BY="Renea Johnston" REVIEW_NO="A023-R" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="2.0">
<COVER_SHEET MODIFIED="2008-11-12 22:20:20 +0100" MODIFIED_BY="Renea Johnston">
<TITLE>Corticosteroid injection for trigger finger in adults</TITLE>
<CONTACT MODIFIED="2008-11-12 22:20:20 +0100" MODIFIED_BY="Renea Johnston"><PERSON ID="8416FB2082E26AA200433359414DDE58" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Cyriac</FIRST_NAME><LAST_NAME>Peters-Veluthamaningal</LAST_NAME><POSITION>General Practitioner</POSITION><EMAIL_1>raju@dds.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of General Practice</DEPARTMENT><ORGANISATION>University Medical Center Groningen</ORGANISATION><ADDRESS_1>Antonius Deusinglaan 1</ADDRESS_1><CITY>Groningen</CITY><ZIP>9713 AV</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31-50-3632963</PHONE_1><FAX_1>+31-50*3632964</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-12 22:20:20 +0100" MODIFIED_BY="Renea Johnston"><PERSON ID="8416FB2082E26AA200433359414DDE58" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Cyriac</FIRST_NAME><LAST_NAME>Peters-Veluthamaningal</LAST_NAME><POSITION>General Practitioner</POSITION><EMAIL_1>raju@dds.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of General Practice</DEPARTMENT><ORGANISATION>University Medical Center Groningen</ORGANISATION><ADDRESS_1>Antonius Deusinglaan 1</ADDRESS_1><CITY>Groningen</CITY><ZIP>9713 AV</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31-50-3632963</PHONE_1><FAX_1>+31-50*3632964</FAX_1></ADDRESS></PERSON><PERSON ID="5643" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Daniëlle</FIRST_NAME><MIDDLE_INITIALS>AWM</MIDDLE_INITIALS><LAST_NAME>van der Windt</LAST_NAME><SUFFIX>PhD</SUFFIX><POSITION>Senior Researcher</POSITION><EMAIL_1>dawm.vanderwindt@vumc.nl</EMAIL_1><EMAIL_2>d.van.der.windt@cphc.keele.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>Department of General Practice </DEPARTMENT><ORGANISATION>EMGO Institute</ORGANISATION><ADDRESS_1>VU University Medical Center </ADDRESS_1><ADDRESS_2>Van der Boechorststraat 7</ADDRESS_2><CITY>Amsterdam</CITY><ZIP>1081 BT</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 444 8354</PHONE_1><PHONE_2>+44 1782 583 927</PHONE_2><FAX_1>+31 20 444 8361</FAX_1></ADDRESS></PERSON><PERSON ID="841ED8AD82E26AA200433359237C289A" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jan</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Winters</LAST_NAME><POSITION>General Practitioner</POSITION><ADDRESS><DEPARTMENT>Department of General Practice</DEPARTMENT><ORGANISATION>University Medical Center Groningen</ORGANISATION><ADDRESS_1>Antonius Deusinglaan 1</ADDRESS_1><CITY>Groningen</CITY><ZIP>9713 AV</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31-50-4061834</PHONE_1></ADDRESS></PERSON><PERSON ID="841CB0CB82E26AA200433359CD4750A0" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Betty</FIRST_NAME><LAST_NAME>Meyboom- de Jong</LAST_NAME><POSITION>Head of the Dept. of General Practice</POSITION><EMAIL_1>b.meyboom@med.rug.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of General Practice</DEPARTMENT><ORGANISATION>University Medical Center Groningen</ORGANISATION><ADDRESS_1>Antonius Deusinglaan 1</ADDRESS_1><CITY>Groningen</CITY><ZIP>9713 AV</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31-50-3632963</PHONE_1><FAX_1>+31-50-3632964</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-13 08:15:28 +1100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="29" MONTH="4" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="13" MONTH="11" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="13" MONTH="11" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2008-04-23 16:41:00 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-04-23 16:41:00 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>CMSG ID A023-R</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="23" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-04-23 16:42:06 +1000" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Department of General Practice, University Medical Center Groningen</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>EMGO Institute, Vrije Universiteit Medical Center Amsterdam</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-13 08:00:54 +1100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-11-13 07:55:11 +1100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-11-13 07:55:11 +1100" MODIFIED_BY="[Empty name]">Local corticosteroid injection for trigger finger</TITLE>
<SUMMARY_BODY MODIFIED="2008-11-13 07:53:46 +1100" MODIFIED_BY="[Empty name]">
<P>This summary of a Cochrane review presents what we know from research about the effect of corticosteroid injection for trigger finger.</P>
<P>Pain and symptoms of people with trigger finger may improve with a corticosteroid injection.</P>
<P>
<B>What is trigger finger and corticosteroid injection?</B>
</P>
<P>Trigger finger is a disease of the tendons of the finger, which makes the finger difficult to straighten.  It causes snapping or locking of the affected finger when flexing or stretching. Sometimes it can cause the hand to become painful. </P>
<P>Corticosteroid injections are shots with a needle into a joint (such as your finger) or a tendon.  Corticosteroids work by reducing the inflammation of the finger.  The injection itself might also help to relieve the pressure on the tendon.</P>
<P>
<B>Best estimate of what happens after a corticosteroid injection:</B>
</P>
<P>37 out of 100 people benefited from corticosteroid injection combined with a painkiller; compared to 17 out of 100 people who benefited following injection with a painkiller only.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-11-13 07:48:51 +1100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2008-11-13 07:48:51 +1100" MODIFIED_BY="[Empty name]">
<P>Trigger finger is a disease of the tendons of the hand leading to triggering (locking) of affected fingers, dysfunction and pain. Available treatments include local injection with corticosteroids, surgery, or splinting.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-11-08 09:26:49 +1100" MODIFIED_BY="[Empty name]">
<P>To summarize the evidence on the efficacy and safety of corticosteroid injections for trigger finger in adults using the following endpoints: treatment success, frequency of triggering or locking, functional status of the affected fingers, and severity of pain of the fingers.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-11-08 09:28:34 +1100" MODIFIED_BY="[Empty name]">
<P>The databases CENTRAL, DARE, MEDLINE (1966 to November 2007), EMBASE (1956 to November 2007), CINAHL (1982 to November 2007), AMED (1985 to November 2007) and PEDro (a physiotherapy evidence database) were searched.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-11-08 11:01:10 +1100" MODIFIED_BY="[Empty name]">
<P>We selected randomized and controlled clinical trials evaluating efficacy and safety of corticosteroid injections for trigger finger in adults.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-11-08 10:18:45 +1100" MODIFIED_BY="[Empty name]">
<P>The databases were searched for titles of eligible studies. After screening abstracts of these studies, full text articles of studies which fulfilled the selection criteria were obtained. Data were extracted using a predefined electronic form. The methodological quality of included trials was assessed by using items from the checklist developed by Jadad and the Delphi list. We planned to extract data regarding information on the primary outcome measures: treatment success, frequency of triggering or locking, and functional impairment of fingers, severity of the trigger finger; and the secondary outcome measures: proportion of patients with side effects, types of side effects, and patient satisfaction with injection.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-11-08 11:01:26 +1100" MODIFIED_BY="[Empty name]">
<P>Two randomized controlled studies were found that involved 63 participants: 34 were allocated to corticosteroids and lidocaine, and 29 were allocated to lidocaine alone. Corticosteroid injection with lidocaine was more effective than lidocaine alone on treatment success at four weeks (relative risk 3.15, 95% CI 1.34 to 7.40). The number needed to treat to benefit was 3. No adverse events or side effects were reported.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-11-08 11:01:35 +1100" MODIFIED_BY="[Empty name]">
<P>The effectiveness of local corticosteroid injections was studied in only two small randomized controlled trials of poor methodological quality. Both studies showed better short-term effects of corticosteroid injection combined with lidocaine compared to lidocaine alone on the treatment success outcome. In one study the effects of corticosteroid injections lasted up to four months. No adverse effects were observed. The available evidence for the effectiveness of intra-tendon sheath corticosteroid injection for trigger finger can be graded as a silver level evidence for superiority of corticosteroid injections combined with lidocaine over injections with lidocaine alone.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-13 08:00:54 +1100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-11-12 09:02:44 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<P>Trigger finger (also known as stenosing tenosynovitis) is a condition that causes triggering, snapping, or locking on flexion of the involved finger. Entrapment of the affected tendon results in difficulty in flexing or extending the finger and is frequently associated with pain in the palm of the hand.</P>
<P>Notta reported the first four cases attended by the physician Nelaton in 1850, and the first review of the literature on this subject was published by Compere in 1933 (<LINK REF="REF-Moore-2000" TYPE="REFERENCE">Moore 2000</LINK>). From the mid-1980s onwards, trigger finger has been suggested to fall under umbrella terms such as 'repetitive strain injury' (RSI) and 'cumulative trauma disorder'. A study of 665 workers at a meat packing plant reported a point prevalence of 14%, suggesting a relation between occupation and trigger finger (<LINK REF="REF-Gorsche-1998" TYPE="REFERENCE">Gorsche 1998</LINK>), although a study by <LINK REF="REF-Trezies-1998" TYPE="REFERENCE">Trezies 1998</LINK> could not confirm this association.</P>
<P>The flexor tendon sheath in the finger is a double-walled, connective tissue cylinder that is held in place by five ring-shaped and three cross-shaped pulleys (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). The triggering phenomenon is caused by incompatibility between the tendon and its sheath, most probably due to thickening of the first annular pulley. On histologic examination the pulley shows fibrous and cartilaginous tissue changes that include the presence of chondrocytes and glycosaminoglycans (mucopolysaccharide) and degenerative changes. These changes are believed to represent adaptations to shear load. Although trigger finger is also known as tenosynovitis, no inflammatory changes were seen in the histologic studies (<LINK REF="REF-Moore-2000" TYPE="REFERENCE">Moore 2000</LINK>).</P>
<P>There is no universally agreed case definition for trigger finger and the diagnosis is made by history and physical examination; there are no specific diagnostic tests. Laboratory tests and radiographic examination techniques are not indicated, unless an underlying cause is suspected (for example infection).</P>
<P>The lifetime prevalence of trigger finger among a group of non-diabetics above the age of 30 years has been estimated at 2.2%. Generally the condition is more common among women than men, and the age distribution is bimodal with one group below six years of age and the other above 40 years of age (most of the affected individuals are in the fifth or sixth decade of their life). Most cases involve a single finger; some have multiple affected fingers and people with multiple affected fingers at presentation are three times more likely to have a subsequent finger affected. Among people without concurrent disease the thumb is the most commonly affected finger, followed by the ring finger and the little finger. The right hand is the most frequently affected. Spontaneous recovery has been reported in 20% to 29% of cases of trigger finger (<LINK REF="REF-Moore-2000" TYPE="REFERENCE">Moore 2000</LINK>).</P>
<P>Trigger finger occurs more commonly in patients with diabetes mellitus (probably due to glucose-induced collagen modifications), carpal tunnel syndrome, Dupuytren's disease, rheumatoid arthritis, amyloidosis, hypothyroidism, mucopolysaccharide storage disorders, and congestive heart failure (<LINK REF="REF-Blyth-1996" TYPE="REFERENCE">Blyth 1996</LINK>; <LINK REF="REF-Chammas-1995" TYPE="REFERENCE">Chammas 1995</LINK>). A separate entity is formed by trigger finger in children, which is a rare disease (0.3% of newborns) where almost always the thumb is affected and the predominant symptom is limited extension (<LINK REF="REF-Rodgers-1994" TYPE="REFERENCE">Rodgers 1994</LINK>; <LINK REF="REF-van-den-Borne-2000" TYPE="REFERENCE">van den Borne 2000</LINK>).</P>
<P>Available treatment modalities for trigger finger are operative (open or percutaneous surgical division of the A1 pulley) and non-operative (corticosteroid injections and splinting). The percentages of participants with trigger finger treated by operation, steroid injection, and splinting are not known. Operative therapy seems to be effective with cure rates of 89% to 97% in non-randomised studies but it is associated with higher cost, longer absence from work, and the possibility of surgical complications (<LINK REF="REF-Turowski-1997" TYPE="REFERENCE">Turowski 1997</LINK>). An explanation for the presumed efficacy of local corticosteroid injections could be that the anti-inflammatory effect reduces the swelling of the A1 pulley (although in histological studies, as mentioned above, inflammation in the affected tissues could not be demonstrated). Corticosteroid injection has been assumed to be as effective as surgical therapy, with reported cure rates ranging from 60% to 92% (<LINK REF="REF-Moore-2000" TYPE="REFERENCE">Moore 2000</LINK>), but there are no studies that compared corticosteroid injections directly to surgical treatment . Splinting appeared to be effective in in 70% of cases compared with 82% receiving an injection (<LINK REF="STD-Patel-1992" TYPE="STUDY">Patel 1992</LINK>). There have been no reports of serious complications of injection therapy, but possible side effects could be steroid flare, tendon-ruptures, local infection, allergic reactions to corticosteroids, and atrophy of subcutaneous fat tissue.</P>
<P>Trigger finger appears to be a fairly common disorder leading to marked discomfort and dysfunction of the hand. Injection with corticosteroids has been suggested to be effective and safe; compared with surgical therapy, it also seems more easy to apply and cost efficient. Therefore, we decided to perform a systematic review on the effectiveness and safety of corticosteroid injections for trigger fingers in adults.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-11-08 10:11:38 +1100" MODIFIED_BY="[Empty name]">
<P>Our objective was to systematically review the evidence from clinical trials on the efficacy and safety of corticosteroid injections for trigger finger in adults.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-08 11:20:35 +1100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-11-08 11:02:25 +1100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2008-11-08 11:02:25 +1100" MODIFIED_BY="[Empty name]">
<P>All randomized controlled trials (RCTs) and controlled clinical trials evaluating local injection with corticosteroids were included in this review.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-11-08 10:12:53 +1100" MODIFIED_BY="[Empty name]">
<P>Only studies of adult populations (older than 18 years) with a clinical diagnosis of trigger finger (triggering with or without locking of a finger or pain at the A1 pulley) and irrespective of the duration of symptoms were included. Studies addressing treatment of trigger finger of infectious origin were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-11-08 10:16:26 +1100" MODIFIED_BY="[Empty name]">
<P>All studies using injectable corticosteroids as treatment were included: any volume, type, and concentration of corticosteroid used; whether a local anaesthetic agent was added or not; and regardless of the injection technique. Studies comparing corticosteroid injection to placebo injection, injection with local anaesthetic, injection with a different type of steroid, splinting, systemic analgesics including non-steroidal anti-inflammatory drugs (NSAIDs), systemic steroids, surgery, combination treatments, or no intervention were included.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-11-08 10:21:30 +1100" MODIFIED_BY="[Empty name]">
<P>Primary:<BR/>
</P>
<UL>
<LI>treatment success, yes or no (definition of treatment success may vary across trials);</LI>
<LI>frequency of triggering or locking of the affected fingers;</LI>
<LI>functional status of the finger (using validated instruments to measure hand function, e.g. arthritis impact measurement scale);</LI>
<LI>severity of pain or tenderness at the base of the digit on the palm of the hand;</LI>
<LI>proportion of patients with side effects of steroid injection.</LI>
</UL>
<P>Secondary:<BR/>
</P>
<UL>
<LI>patient satisfaction (using validated questionnaires).</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-08 10:28:29 +1100" MODIFIED_BY="[Empty name]">
<P>The following electronic databases were searched:<BR/>
</P>
<UL>
<LI>CENTRAL (<I>The Cochrane Library</I>);</LI>
<LI>MEDLINE (Ovid platform) (1966 to November 2007);</LI>
<LI>EMBASE (Ovid platform) (1956 to November 2007);</LI>
<LI>CINAHL (Ovid platform) (1982 to November 2007);</LI>
<LI>AMED (Ovid platform) (1985 to November 2007);</LI>
<LI>PEDro (the physiotherapy evidence database);</LI>
<LI>DARE (The Database of Abstracts of Reviews of Effectiveness);</LI>
<LI>Dissertation abstracts.</LI>
</UL>
<P>The search strategy was developed for MEDLINE and modified as necessary for the other databases.</P>
<P>Complete search strategies for each database are provided in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>; <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>; <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>; <LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>; <LINK REF="APP-08" TYPE="APPENDIX">Appendix 8</LINK>. The references of all relevant publications (RCTs and reviews) were checked to identify additional trials. Content experts were contacted for unpublished data. There were no language restrictions.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-11-08 11:20:35 +1100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Selection of studies</HEADING>
<P>Two review authors independently selected trials for inclusion in this review, based on the content of the title and abstracts obtained through electronic searching of the databases. Each review author's selection was compared. Any discrepancies in opinion about eligibility of a trial were resolved by discussion and consensus by the two review authors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality appraisal</HEADING>
<P>Two review authors independently extracted all data. Each trial was assessed by using a combination of an established quality assessment tool developed by Jadad (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>) and the Delphi list (<LINK REF="REF-Verhagen-1998" TYPE="REFERENCE">Verhagen 1998</LINK>). The quality items assessed were:<BR/>1. randomization;<BR/>2. concealment of allocation;<BR/>3. blinding of outcome assessor, care provider, and patient;<BR/>4. reporting of withdrawals and dropouts;<BR/>5. similarity of groups at baseline regarding most important prognostic indicators;<BR/>6. specification of eligibility criteria;<BR/>7. availability of point estimates and measures of variability of primary outcome measures;<BR/>8. use of intention-to-treat analysis.</P>
<P>Each criterion was rated as positive, negative, or inconclusive (if insufficient information was presented).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>Details regarding the study population, interventions, treatment periods, length of follow up, complications, baseline demographic data, and baseline and end of study outcome measures were extracted using a pre-defined electronic form, by two review authors. Short-term outcomes were arbitrarily defined as outcomes up to three months after the intervention and long-term outcomes as outcomes one year post-intervention, or later. Referring back to the original article and establishing consensus resolved differences in data extraction. A third review author was consulted to help resolve differences.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Analysis</HEADING>
<P>For continuous data, weighted mean differences (MD) were planned to be calculated for outcomes measured using the same scale; and when the same outcomes were measured using different scales, standardized mean differences (SMD) were to be used. Absolute and relative differences in the change from baseline were to be calculated for continuous outcomes. Absolute benefit was to be calculated as the improvement in the treatment group minus the improvement in the control group, in original units. Relative difference in the change from baseline was to be calculated as the absolute benefit divided by the baseline mean.</P>
<P>For dichotomous data the results for each study were presented as relative risk and the number needed to treat (NNT).</P>
<SUBSECTION>
<HEADING LEVEL="4">Heterogeneity</HEADING>
<P>To assess heterogeneity of trial results the Cochrane Chi<SUP>2 </SUP>test and I<SUP>2 </SUP>statistic were planned to be used. In case of significant statistical heterogeneity potential sources were planned to be explored by subgroup analysis. Since clinical and methodological diversity always occur in a meta-analysis, statistical heterogeneity is inevitable (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). The test for heterogeneity is irrelevant to the choice of analysis; accordingly the random-effects model was used by default as it is identical to the fixed-effect model if there is no heterogeneity (I<SUP>2 </SUP>= 0%). In order to assess and quantify the possible magnitude of inconsistency (that is heterogeneity) across studies, we used I<SUP>2</SUP> with a rough guide for interpretation as follows: 0% to 40% might not be important; 30% to 60% may represent moderate heterogeneity; 50% to 90% may represent substantial heterogeneity; 75% to 100% shows considerable heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analysis</HEADING>
<P>Subgroup analysis was planned in regard to the following aspects:</P>
<UL>
<LI>'idiopathic' or trigger finger secondary to diabetes;</LI>
<LI>duration of symptoms at baseline, short if symptoms were present for up to four weeks, intermediate if symptoms were present for one month to one year, and long if symptoms were present for one year or longer.</LI>
<LI>trial design, RCT or controlled clinical trial.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clinical relevance tables</HEADING>
<P>Clinical relevance tables were compiled for primary outcomes under the 'Additional tables' to improve the readability of the review. For dichotomous outcomes, the weighted absolute risk difference was calculated using the risk difference (RD) statistic in RevMan. RR-1 calculates the weighted relative per cent change. The number needed to treat (NNT) was calculated from the control group event rate (unless the population event rate was known), and the relative risk using the Visual Rx NNT calculator (<LINK REF="REF-Cates-2004" TYPE="REFERENCE">Cates 2004</LINK>). This was done for the primary outcomes measured.</P>
<P>Continuous outcome tables were also planned to be presented. Weighted absolute change was planned to be calculated from the weighted mean difference (WMD) statistic in RevMan when trials using the same scale were pooled. For outcomes pooled on different scales, the standardized mean difference (SMD) was planned to be multiplied by the baseline standard deviation in the control group to obtain the weighted absolute change. Relative per cent change from baseline was planned to be calculated as the absolute benefit divided by the baseline mean of the control group. NNT was planned to be calculated using the Wells calculator available at the Cochrane Musculoskeletal Group editorial office. The minimal clinically important difference (MCID) for each outcome was planned to be determined for input into the calculator.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Grading of evidence</HEADING>
<P>The evidence obtained in this systematic review was finally graded according to conventions as proposed by the Cochrane Musculoskeletal Group (<LINK REF="REF-Tugwell-2004" TYPE="REFERENCE">Tugwell 2004</LINK>).</P>
<P>Platinum: a published systematic review that has at least two individual controlled trials each satisfying the following.<BR/>Sample sizes of at least 50 per group: if these do not find a statistically significant difference, they are adequately powered for a 20% relative difference in the relevant outcome.<BR/>Blinding of patients and assessors for outcomes.<BR/>Handling of withdrawals &gt; 80% follow up (imputations based on methods such as 'last observation carried forward' (LOCF) are acceptable).<BR/>Concealment of treatment allocation.</P>
<P>Gold: at least one RCT meeting all of the following criteria for the major outcome(s) as reported.<BR/>Sample sizes of at least 50 per group: if these do not find a statistically significant difference, they are adequately powered for a 20% relative difference in the relevant outcome.<BR/>Blinding of patients and assessors for outcomes.<BR/>Handling of withdrawals &gt; 80% follow up (imputations based on methods such as LOCF are acceptable).<BR/>Concealment of treatment allocation.</P>
<P>Silver: a systematic review or randomized trial that does not meet the above criteria. Silver ranking would also include evidence from at least one study of non-randomised cohorts that did and did not receive the therapy, or evidence from at least one high quality case-control study. A randomized trial with a 'head-to-head' comparison of agents would be considered silver level ranking unless a reference were provided to a comparison of one of the agents to placebo showing at least a 20% relative difference.</P>
<P>Bronze: the bronze ranking is given to evidence if at least one high quality case series without controls (including simple before and after studies in which patients act as their own control) or if the conclusion is derived from expert opinion based on clinical experience without reference to any of the foregoing (for example, argument from physiology, bench research, or first principles).</P>
<P>This review will be updated two years after publication.</P>
</SUBSECTION>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-13 08:00:54 +1100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-11-13 08:00:54 +1100" MODIFIED_BY="[Empty name]">
<P>Our search resulted in 230 titles from a combined search in MEDLINE, EMBASE, AMED and CINAHL. No titles were found in PEDro, CENTRAL, DARE, and Dissertation abstracts. After screening the titles and abstracts, 16 possible studies were selected for further evaluation (<LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK>; <LINK REF="STD-Benson-1997" TYPE="STUDY">Benson 1997</LINK>; <LINK REF="STD-Boyer-2004" TYPE="STUDY">Boyer 2004</LINK>; <LINK REF="STD-Clark-1973" TYPE="STUDY">Clark 1973</LINK>; <LINK REF="STD-Kraemer-1990" TYPE="STUDY">Kraemer 1990</LINK>; <LINK REF="STD-Lambert-1992" TYPE="STUDY">Lambert 1992</LINK>; <LINK REF="STD-Lopez-1991" TYPE="STUDY">Lopez 1991</LINK>; <LINK REF="STD-Maneerit-2000" TYPE="STUDY">Maneerit 2000</LINK>; <LINK REF="STD-Maneerit-2003" TYPE="STUDY">Maneerit 2003</LINK>; <LINK REF="STD-McGrath-1984" TYPE="STUDY">McGrath 1984</LINK>; <LINK REF="STD-Murphy-1995" TYPE="STUDY">Murphy 1995</LINK>; <LINK REF="STD-Patel-1992" TYPE="STUDY">Patel 1992</LINK>; <LINK REF="STD-Patel-1997" TYPE="STUDY">Patel 1997</LINK>; <LINK REF="STD-Povlsen-2004" TYPE="STUDY">Povlsen 2004</LINK>; <LINK REF="STD-Stratz-2002" TYPE="STUDY">Stratz 2002</LINK>; <LINK REF="STD-Taras-1998" TYPE="STUDY">Taras 1998</LINK>). After retrieving full text articles of these 16 reports, six appeared to be non-randomized (<LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK>; <LINK REF="STD-Benson-1997" TYPE="STUDY">Benson 1997</LINK>; <LINK REF="STD-Clark-1973" TYPE="STUDY">Clark 1973</LINK>; <LINK REF="STD-Kraemer-1990" TYPE="STUDY">Kraemer 1990</LINK>; <LINK REF="STD-Patel-1992" TYPE="STUDY">Patel 1992</LINK>; <LINK REF="STD-Patel-1997" TYPE="STUDY">Patel 1997</LINK>), three did not study trigger finger (<LINK REF="STD-Lopez-1991" TYPE="STUDY">Lopez 1991</LINK>; <LINK REF="STD-Povlsen-2004" TYPE="STUDY">Povlsen 2004</LINK>; <LINK REF="STD-Stratz-2002" TYPE="STUDY">Stratz 2002</LINK>), three did not study one of the comparisons of interest as two compared operative treatment (percutaneous release) preceded by steroid injection to steroid injection alone (<LINK REF="STD-Maneerit-2000" TYPE="STUDY">Maneerit 2000</LINK>; <LINK REF="STD-Maneerit-2003" TYPE="STUDY">Maneerit 2003</LINK>) and one compared intra-sheath injection to subcutaneous injection (<LINK REF="STD-Taras-1998" TYPE="STUDY">Taras 1998</LINK>). Of the remaining two studies, one was a review article (<LINK REF="STD-McGrath-1984" TYPE="STUDY">McGrath 1984</LINK>) and one a comment on a reported trial (<LINK REF="STD-Boyer-2004" TYPE="STUDY">Boyer 2004</LINK>). The 14 excluded trials, and details of why they failed to meet the inclusion criteria for this review, are outlined in the table 'Characteristics of excluded studies'.</P>
<P>We were also aware of an ongoing randomised controlled trial assessing effectiveness of corticosteroid injections in the setting of primary care, but the results of the study were not published yet when our search was performed (see <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>).</P>
<P>The two included studies were controlled trials comparing the efficacy of steroid injection with lidocaine injections in the setting of secondary care. One included 41 fingers of 41 participants with a diagnosis of trigger finger (two participants were lost to follow up therefore only 39 participants were included in the analysis) and compared the effectiveness of injection of methylprednisolone (0.5 ml) combined with 1% lidocaine (0.5 ml) to 1% lidocaine alone (<LINK REF="STD-Lambert-1992" TYPE="STUDY">Lambert 1992</LINK>). Treatment success in this study (defined as complete resolution of symptoms or sufficiently improved that further treatment was not necessary) was assessed one month after injection. The second study included 24 fingers in 24 participants and compared the effectiveness of betamethasone (1ml) combined with lidocaine (3 ml) to injection with 1% lidocaine (4 ml) alone. Treatment success (defined as participants becoming asymptomatic) was assessed immediately after injection, and three weeks and four months after injection (<LINK REF="STD-Murphy-1995" TYPE="STUDY">Murphy 1995</LINK>). A detailed description of the two included studies can be found in the table 'Characteristics of included studies'.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-11-08 11:16:37 +1100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Randomization</HEADING>
<P>Both studies used pseudo-randomization, either allocating patients based on date of birth (<LINK REF="STD-Lambert-1992" TYPE="STUDY">Lambert 1992</LINK>) or on day of presentation (<LINK REF="STD-Murphy-1995" TYPE="STUDY">Murphy 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Allocation concealment</HEADING>
<P>Both reports did not mention how allocation concealment was realized.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Participant flow and follow up</HEADING>
<P>In the study by <LINK REF="STD-Lambert-1992" TYPE="STUDY">Lambert 1992</LINK> 41 participants were enrolled and randomized: 20 participants were allocated to steroid injection, 21 participants allocated to lidocaine injection; all participants received the allocated intervention; and two participants in the lidocaine group were lost to follow up and excluded from the analysis. In the study by <LINK REF="STD-Murphy-1995" TYPE="STUDY">Murphy 1995</LINK> 24 participants were enrolled and randomised: 14 participants were allocated to steroid injection, 10 participants were allocated to lidocaine injection; all participants received the allocated intervention and were analysed since none of the enrolled cases were lost to follow up.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Summary of quality items</HEADING>
<P>In the study by <LINK REF="STD-Lambert-1992" TYPE="STUDY">Lambert 1992</LINK> the outcome assessor was blinded, there was reporting of withdrawals and dropouts, eligibility criteria were specified, and point estimates and measures of variability of primary outcome measures were available. However, concealment of allocation, blinding of care provider, blinding of patients, and similarity of groups at baseline regarding most important prognostic indicators were unclear and no intention-to-treat analysis was used.</P>
<P>In the <LINK REF="STD-Murphy-1995" TYPE="STUDY">Murphy 1995</LINK> study the outcome assessor and patient were blinded, but the care provider was not. Withdrawals and dropouts were reported, an intention-to treat analysis was used, but no concealment of allocation was used. It was unclear whether the two treatment groups were similar at baseline regarding the most important prognostic indicators, and whether point estimates and measures of variability of primary outcomes were available (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other shortcomings</HEADING>
<P>Both trials did not specify which specific diagnostic criteria were used for the diagnosis of trigger finger, how many cases were assessed for eligibility prior to enrolment; and insufficient information of baseline demographic and clinical characteristics was provided to make a judgement about comparability of corticosteroid and control groups.</P>
<P>For further details see the table of 'Characteristics of included studies' and 'Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>' for methodological quality of included studies.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-11-08 11:25:28 +1100" MODIFIED_BY="[Empty name]">
<P>The only primary outcome measure assessed in both studies was the dichotomous outcome of treatment success. In the study by <LINK REF="STD-Lambert-1992" TYPE="STUDY">Lambert 1992</LINK> this was defined as complete resolution of symptoms or sufficient improvement for further treatment to be unnecessary, and in the study by <LINK REF="STD-Murphy-1995" TYPE="STUDY">Murphy 1995</LINK> it was defined as being asymptomatic. There were no data available regarding frequency of triggering, severity of pain, and functional status of the hand. Regarding secondary outcome measures, both studies stated that there were no adverse reactions or complications (it was not clear whether this was systematically assessed). Patient satisfaction with treatment was not assessed in either study.<BR/>Because of the small number of studies and included patients, and since the two included studies seemed homogenous, we refrained from subgroup and sensitivity analyses.
<BR/>

<BR/>In the study by <LINK REF="STD-Lambert-1992" TYPE="STUDY">Lambert 1992</LINK> treatment success assessed one month after injection was 45% (9/20) in the methylprednisolone + lidocaine group and 16% (3/19) in the lidocaine alone group. Absolute risk reduction was 0.292 (95% CI 0.017 to 0.567), relative risk 2.85 (95% CI 0.91 to 8.96) with a number needed to treat (NNT) of 3 (95% CI 2 to 58).</P>
<P>In the study by <LINK REF="STD-Murphy-1995" TYPE="STUDY">Murphy 1995</LINK> treatment success assessed three weeks after injection therapy was 71% (10/14) in the betamethasone + lidocaine group and 20% (2/10)in the lidocaine alone group. Absolute risk reduction was 0.514 (95% CI 0.165 to 0.864), relative risk 3.57 (95% CI 0.99 to 12.88) with a NNT of 2 (95% CI 1 to 6).<BR/>Four months after injection therapy treatment success was 64% (9/14) in the betamethasone + lidocaine group and 20% (2/10) in the lidocaine alone group, absolute risk reduction 0.514 (95% CI 0.165 to 0.864), relative risk 3.21v(95% CI 0.88 to 11.79), and the NNT was 2 (95% CI 1 to 6).</P>
<P>Pooling of the two studies resulted in a total of 63 participants. Corticosteroid injections with lidocaine showed significantly more effectiveness within four weeks than lidocaine injection alone (RR 3.15, 95% CI 1.34 to 7.40). The control event rate was 17.2 % for the pooled group, the weighted absolute risk difference was 38% (95% CI 16 to 59) and the NNT was 3 (95% CI 2 to 18) (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). 
<BR/>
Thus, our data indicated that an expected additional 37 out of 100 participants benefited from the combination of lidocaine and steroid injection; opposed to 17 patients who benefited following (control) therapy with lidocaine only (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-11-08 11:35:18 +1100" MODIFIED_BY="[Empty name]">
<P>In this review, including two randomized controlled trials (RCTs) with a total of 63 participants (<LINK REF="STD-Lambert-1992" TYPE="STUDY">Lambert 1992</LINK>; <LINK REF="STD-Murphy-1995" TYPE="STUDY">Murphy 1995</LINK>), we found silver level evidence for superiority of intra-tendon sheath corticosteroid injections combined with lidocaine over injections with lidocaine alone. In one of the included studies (<LINK REF="STD-Murphy-1995" TYPE="STUDY">Murphy 1995</LINK>) the effects of corticosteroid injections lasted up to four months. Both studies did not report any adverse effects.</P>
<P>However, there were only two RCTs available which fulfilled the inclusion criteria. The total number of participants included in this review was small, thereby possibly reflecting publication bias. Furthermore, the methodological quality of the two studies was poor and there were some flaws in the quality of reporting.</P>
<P>Effectiveness (using treatment success as the outcome measure) was consistent in the two included studies and the effect size was considerable. We found that for effectiveness within four weeks the relative risk was 3.15, and that the number needed to treat (NNT) was 3; meaning that there is a 3.15 times greater probability of participants treated with local corticosteroid injection to achieve treatment success than for participants treated with lidocaine injection alone, and that three participants have to be treated by local corticosteroid injection to achieve treatment success in one extra participant. For effectiveness at four months (available only for the 24 participants in the study by <LINK REF="STD-Murphy-1995" TYPE="STUDY">Murphy 1995</LINK>) the relative risk was 3.21 and the NNT was 2.</P>
<P>The two trials suggest that corticosteroid injection therapy is effective and safe for the treatment of trigger finger, but these effects need to be confirmed in larger, well-designed randomized trials.</P>
<P>Several other questions remain to be answered. First, it is not clear whether injection therapy is superior to surgical treatment or splinting, in efficacy or safety. Some retrospective studies have investigated the effectiveness of surgery, reporting treatment success in 67% to 90% of the cases, but this has never been assessed in RCTs and has never been compared directly to injection therapy or splinting. Second, we do not know which diagnostic criteria and outcome measures are valid to use for studies of interventions for trigger finger. At this moment in time there is no universally agreed case definition for trigger finger and there are no validated instruments for measuring symptom severity and functional disability (ideally with known minimal clinically important differences). Third, the two trials analysed in this review were performed in the setting of secondary care and generalizability to other settings (for example primary care) remains to be established. Finally, this review suggests efficacy up to four months, but long-term efficacy still remains to be clarified.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-11-08 11:38:56 +1100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2008-11-08 11:36:55 +1100" MODIFIED_BY="[Empty name]">
<P>There is silver level evidence that corticosteroid injections are effective for the treatment of trigger finger, but the implications for daily clinical practice may be limited by the fact that the evidence we found is based on two small studies of poor quality, performed in the setting of secondary care, and there were only data available for effectiveness up to four months. However, corticosteroid injection is an easily applicable treatment modality, not expensive, and less invasive than surgery. Therefore, we feel that the initial treatment for patients should be corticosteroid injection rather than surgery. Other non-invasive interventions such as splinting (which was not evaluated in this review) may also be appropriate first-line interventions.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-11-08 11:38:56 +1100" MODIFIED_BY="[Empty name]">
<P>A case definition for trigger finger should be formulated for research purposes. Validated and relevant outcome measures for trigger finger should be developed. Future RCTs should have adequate sample sizes, better methodological quality (especially adequate randomization procedures and allocation concealment), and the findings should be reported according to the CONSORT statement. More comparison studies are needed, comparing corticosteroid injections to surgery and splinting; comparing different types and dosages of corticosteroids; and effectiveness in different types of healthcare settings (for example primary care). Future studies should also address the natural course of trigger finger.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-11-08 11:41:22 +1100" MODIFIED_BY="[Empty name]">
<P>We would like to thank Louise Falzon (trial search coordinator of the Cochrane Musculoskeletal Group) for her assistance in developing the search strategy and performing the searches, and the coordinators of the Australian Editorial Base of the Musculoskeletal Group, Miranda Cumpston and Renea Johnston, for their assistance in writing this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2008-11-08 11:43:15 +1100" MODIFIED_BY="[Empty name]">
<P>CP has conducted an RCT (Groningen Hand and Wrist Injection Therapy Trial - HAWITT) assessing the efficacy and safety of corticosteroid injections for trigger finger, De Quervain's tenosynovitis, and carpal tunnel syndrome in a primary care population. The HAWITT trial was sponsored by an unrestricted educational grant from the pharmaceutical company Bristol-Myers Squibb.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-11-08 11:41:42 +1100" MODIFIED_BY="[Empty name]">
<P>CP: main author, involved in all aspects of the review.<BR/>DW: text of review, data extraction and analysis.<BR/>JW: text of review, data extraction and analysis.<BR/>BM: text of review, selection of studies.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-12 08:41:54 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<STUDIES MODIFIED="2008-11-12 08:41:54 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<INCLUDED_STUDIES MODIFIED="2008-11-08 12:09:14 +1100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Lambert-1992" MODIFIED="2008-11-08 12:08:55 +1100" MODIFIED_BY="[Empty name]" NAME="Lambert 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-11-08 12:08:55 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lambert MA, Morton RJ, Sloan JP</AU>
<TI>Controlled study of the use of local steroid injection in the treatment of trigger finger and thumb</TI>
<SO>The Journal of Hand Surgery</SO>
<YR>1992</YR>
<VL>17</VL>
<NO>1</NO>
<PG>69-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murphy-1995" MODIFIED="2008-11-08 12:09:14 +1100" MODIFIED_BY="[Empty name]" NAME="Murphy 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-11-08 12:09:14 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murphy D, Failla JM, Koniuch MP</AU>
<TI>Steroid versus placebo injection for trigger finger</TI>
<SO>The Journal of Hand Surgery</SO>
<YR>1995</YR>
<VL>20</VL>
<NO>4</NO>
<PG>628-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-11-08 12:10:24 +1100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1991" NAME="Anderson 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson B, Kaye S</AU>
<TI>Treatment of flexor tenosynovitis of the hand ("trigger finger") with corticosteroids. A prospective study of the response to local injection</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1991</YR>
<VL>151</VL>
<NO>1</NO>
<PG>153-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benson-1997" MODIFIED="2008-11-08 12:09:42 +1100" MODIFIED_BY="[Empty name]" NAME="Benson 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-11-08 12:09:42 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benson LS, Ptaszek AJ</AU>
<TI>Injection versus surgery in the treatment of trigger finger</TI>
<SO>The Journal of Hand Surgery</SO>
<YR>1997</YR>
<VL>22</VL>
<NO>1</NO>
<PG>138-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boyer-2004" NAME="Boyer 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boyer M</AU>
<TI>Percutaneous release with steroid injection was more effective than steroid injection alone for trigger thumb</TI>
<SO>Journal of Bone and Joint Surgery</SO>
<YR>2004</YR>
<VL>86</VL>
<NO>5</NO>
<PG>1103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clark-1973" NAME="Clark 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clark DD</AU>
<TI>The efficacy of local steroid injection in the treatment of stenosing tenovaginitis</TI>
<SO>Plastic and Reconstructive Surgery</SO>
<YR>1973</YR>
<VL>51</VL>
<NO>2</NO>
<PG>179-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kraemer-1990" NAME="Kraemer 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kraemer A</AU>
<TI>Stenosing flexor tenosynovitis</TI>
<SO>Southern Medical Journal</SO>
<YR>1991</YR>
<VL>151</VL>
<NO>1</NO>
<PG>153-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lopez-1991" NAME="Lopez 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lopez A, Plas JN, Charlot J</AU>
<TI>Percutaneous treatment for tenosynovitis, with the association dexamethazone-salicylate solution - A double blind study</TI>
<SO>Rhumatologie</SO>
<YR>1991</YR>
<VL>43</VL>
<NO>6</NO>
<PG>171-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maneerit-2000" NAME="Maneerit 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maneerit J, Apimonbutr P, Budhraja N</AU>
<TI>Percutaneous release of trigger digit with steroid injection compared with steroid injection alone: a prospective, randomized study of one hundred and nine digits</TI>
<SO>The Thai Journal of Orthopedic Surgery</SO>
<YR>2000</YR>
<VL>25</VL>
<NO>2</NO>
<PG>63-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maneerit-2003" NAME="Maneerit 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maneerit J</AU>
<TI>Trigger thumb: results of a prospective randomised study of percutaneous release with steroid injection versus steroid injection alone</TI>
<SO>The Journal of Hand Surgery</SO>
<YR>2003</YR>
<VL>28</VL>
<NO>6</NO>
<PG>586</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGrath-1984" NAME="McGrath 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McGrath MH</AU>
<TI>Local steroid therapy in the hand</TI>
<SO>The Journal of Hand Surgery</SO>
<YR>1984</YR>
<VL>9</VL>
<NO>6</NO>
<PG>915-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patel-1992" NAME="Patel 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patel MR</AU>
<TI>Trigger fingers and thumb: when to splint, inject or operate</TI>
<SO>The Journal of Hand Surgery</SO>
<YR>1992</YR>
<VL>17</VL>
<NO>1</NO>
<PG>110-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patel-1997" NAME="Patel 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patel R</AU>
<TI>Percutaneous release of trigger digit with and without cortisone injection</TI>
<SO>The Journal of Hand Surgery</SO>
<YR>1997</YR>
<VL>22</VL>
<NO>1</NO>
<PG>150</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Povlsen-2004" MODIFIED="2008-11-08 11:51:38 +1100" MODIFIED_BY="[Empty name]" NAME="Povlsen 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-11-08 11:51:38 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Povlsen B</AU>
<TI>Basal joint osteoarthritis of the thumb: a prospective trial of steroid injection and splinting</TI>
<SO>The Journal of Hand Surgery</SO>
<YR>2004</YR>
<VL>29</VL>
<NO>5</NO>
<PG>959</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stratz-2002" NAME="Stratz 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stratz T</AU>
<TI>Local treatment of tendinopathies: a comparison between tropisetron and depot corticosteroids combined with local anesthetics</TI>
<SO>Scandinavian Journal of Rheumatology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>6</NO>
<PG>366-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taras-1998" MODIFIED="2008-11-08 12:10:24 +1100" MODIFIED_BY="[Empty name]" NAME="Taras 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-11-08 12:10:24 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taras JS, Raphael JS, Pan WT, Movagharnia F et al</AU>
<TI>Corticosteroid injections for trigger digits: is intrasheath injection necessary?</TI>
<SO>The Journal of Hand Surgery</SO>
<YR>1998</YR>
<VL>23</VL>
<NO>4</NO>
<PG>717-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2008-11-12 08:41:54 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Peters-2007" MODIFIED="2008-11-12 08:41:54 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal" NAME="Peters 2007" YEAR="2007">
<IDENTIFIERS MODIFIED="2008-11-12 08:41:54 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<IDENTIFIER MODIFIED="2008-11-12 08:41:40 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal" TYPE="ISRCTN" VALUE="53171398"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-12 08:28:15 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-12 08:28:15 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<REFERENCE ID="REF-Blyth-1996" MODIFIED="2008-11-08 12:10:53 +1100" MODIFIED_BY="[Empty name]" NAME="Blyth 1996" TYPE="JOURNAL_ARTICLE">
<AU>Blyth MJ, Ross DJ</AU>
<TI>Diabetes and trigger finger</TI>
<SO>The Journal of Hand Surgery</SO>
<YR>1996</YR>
<VL>21</VL>
<NO>2</NO>
<PG>244-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cates-2004" MODIFIED="2008-10-29 10:35:22 +1100" MODIFIED_BY="[Empty name]" NAME="Cates 2004" TYPE="OTHER">
<AU>Cates C</AU>
<TI>Visual Rx</TI>
<SO>http://www.nntonline.net/</SO>
<YR>(accessed 27 June 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chammas-1995" MODIFIED="2008-11-08 12:11:16 +1100" MODIFIED_BY="[Empty name]" NAME="Chammas 1995" TYPE="JOURNAL_ARTICLE">
<AU>Chammas M, Bousquet P, Renard E, Poirier JL et al</AU>
<TI>Dupuytren's disease, carpal tunnel syndrome, trigger finger, and diabetes</TI>
<SO>The Journal of Hand Surgery</SO>
<YR>1995</YR>
<VL>20</VL>
<NO>1</NO>
<PG>109-14</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gorsche-1998" MODIFIED="2008-11-08 11:55:03 +1100" MODIFIED_BY="[Empty name]" NAME="Gorsche 1998" TYPE="JOURNAL_ARTICLE">
<AU>Gorsche R, Wiley JP, Renger R, Brant R, Gemer TY, Sasyniuk TM</AU>
<TI>Prevalence and incidence of stenosing flexor tenosynovitis (trigger finger) in a meat-packing plant</TI>
<SO>Journal of Occupational and Environmental Medicine</SO>
<YR>1998</YR>
<VL>40</VL>
<NO>6</NO>
<PG>556-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2008-11-08 11:55:41 +1100" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JA, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2008-10-29 10:35:22 +1100" MODIFIED_BY="[Empty name]" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="13"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moore-2000" MODIFIED="2008-10-29 10:35:22 +1100" MODIFIED_BY="[Empty name]" NAME="Moore 2000" TYPE="JOURNAL_ARTICLE">
<AU>Moore JS</AU>
<TI>Flexor tendon entrapment of the digits (trigger finger and trigger thumb)</TI>
<SO>The Journal of Occupational and Environmental Medicine</SO>
<YR>2000</YR>
<VL>42</VL>
<NO>5</NO>
<PG>526-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rodgers-1994" MODIFIED="2008-11-08 12:11:39 +1100" MODIFIED_BY="[Empty name]" NAME="Rodgers 1994" TYPE="JOURNAL_ARTICLE">
<AU>Rodgers WB, Waters PM</AU>
<TI>Incidence of trigger digits in newborns</TI>
<SO>The Journal of Hand Surgery</SO>
<YR>1994</YR>
<VL>19</VL>
<NO>3</NO>
<PG>364-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Trezies-1998" MODIFIED="2008-11-08 12:12:23 +1100" MODIFIED_BY="[Empty name]" NAME="Trezies 1998" TYPE="JOURNAL_ARTICLE">
<AU>Trezies AJ, Lyons AR, Fielding K, Davis TR</AU>
<TI>Is occupation an aetiological factor in the development of trigger finger?</TI>
<SO>The Journal of Hand Surgery</SO>
<YR>1998</YR>
<VL>23</VL>
<NO>4</NO>
<PG>539-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tugwell-2004" MODIFIED="2008-10-29 10:35:22 +1100" MODIFIED_BY="[Empty name]" NAME="Tugwell 2004" TYPE="BOOK">
<AU>Tugwell P, Shea B, Boers M, Simons L et al</AU>
<SO>Evidence-based Rheumatology</SO>
<YR>2004</YR>
<PB>BMJ Publishing Group</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Turowski-1997" MODIFIED="2008-11-08 12:12:38 +1100" MODIFIED_BY="[Empty name]" NAME="Turowski 1997" TYPE="JOURNAL_ARTICLE">
<AU>Turowski GA, Zdankiewicz PD, Thomson JG</AU>
<TI>The results of surgical treatment of trigger finger</TI>
<SO>The Journal of Hand Surgery</SO>
<YR>1997</YR>
<VL>22</VL>
<NO>1</NO>
<PG>145-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-den-Borne-2000" MODIFIED="2008-10-29 10:35:22 +1100" MODIFIED_BY="[Empty name]" NAME="van den Borne 2000" TYPE="JOURNAL_ARTICLE">
<AU>van den Borne MP, Custers FJ, van der Aa JP, van der Eijken JW</AU>
<TI>'Trigger thumb' in 38 children: good short-term and long-term results</TI>
<SO>Nederlands Tijdschrift voor Geneeskunde</SO>
<YR>2000</YR>
<VL>144</VL>
<NO>8</NO>
<PG>374-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Verhagen-1998" MODIFIED="2008-10-29 10:35:22 +1100" MODIFIED_BY="[Empty name]" NAME="Verhagen 1998" TYPE="JOURNAL_ARTICLE">
<AU>Verhagen A, de Vet HCW, de Bie RA, Kessels AGH et al</AU>
<TI>The delphi list: a criteria list for quality assessment of randomised clinical trials for conducting systematic reviews developed by delphi consensus</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1998</YR>
<VL>51</VL>
<NO>12</NO>
<PG>1235-41</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-11-12 09:34:40 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-11-08 11:47:04 +1100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-11-08 11:44:58 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lambert-1992">
<CHAR_METHODS MODIFIED="2008-11-08 11:43:33 +1100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled study: allocation of intervention based on date of birth.<BR/>Method of blinding unclear.<BR/>Parallel groups.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-08 11:44:15 +1100" MODIFIED_BY="[Empty name]">
<P>Secondary care.<BR/>Adults.<BR/>Inclusion criteria: symptoms of trigger finger for at least 3 months.<BR/>Exclusion criteria: insulin dependent diabetes mellitus, rheumatoid arthritis, eczema, current infection or previous injection in the past 3 months.<BR/>Mean age 54 years.<BR/>25 female, 16 male.<BR/>Average duration of symptoms 6.5 months.<BR/>Flow of patients:<BR/>-41 fingers enrolled<BR/>-41 fingers randomised<BR/>-20 fingers allocated to methylprednisolone injection, 21 to lidocaine injection<BR/>-41 fingers received allocated intervention<BR/>-lost to follow up: 2 fingers in the lidocaine group<BR/>-analysed: 20 fingers in steroid injection group, 19 fingers in lidocaine group.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-08 11:44:58 +1100" MODIFIED_BY="[Empty name]">
<P>Group 1: 0.5 ml (20 mg) methylprednisolone<BR/>+ 0.5 ml 1% lidocaine.<BR/>Group 2: 1 ml 1% lidocaine.<BR/>Technique: intra-sheath injection.<BR/>Number of injections: 1.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-02 03:55:59 +1000" MODIFIED_BY="[Empty name]">
<P>Assessment 1 month after injection.<BR/>Definition of treatment success: complete resolution of symptoms or sufficiently improved that further treatment was not necessary.<BR/>Definition of treatment failure: persistent clicking or locking requiring retreatment.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-08 11:47:04 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Murphy-1995">
<CHAR_METHODS MODIFIED="2008-11-08 11:45:27 +1100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled study: allocation of intervention based on date of birth.<BR/>Method of blinding unclear.<BR/>Parallel groups.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-08 11:45:52 +1100" MODIFIED_BY="[Empty name]">
<P>Secondary care.<BR/>Adults.<BR/>Inclusion criteria: primary trigger finger<BR/>Exclusion criteria: participants with rheumatoid arthritis, diabetes mellitus, prior damage of tendons, prior diagnosis of trigger finger or locked finger.<BR/>Mean age: betamethasone+lidocaine group 54 years, lidocaine group: 62 years.<BR/>15 female, 9 male.<BR/>Flow of patients:<BR/>-24 fingers enrolled<BR/>-24 fingers randomised<BR/>-14 fingers allocated to methylprednisolone injection, 10 to lidocaine injection<BR/>-24 fingers received allocated intervention<BR/>-lost to follow up: 0<BR/>-analysed: 14 fingers in steroid injection group, 10 fingers in lidocaine group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-08 11:47:04 +1100" MODIFIED_BY="[Empty name]">
<P>Group 1: 1 ml betamethasone + 3 ml 1% lidocaine.<BR/>Group 2: 4ml 1% lidocaine.<BR/>Technique: intra-sheath injection.<BR/>Number of injections: 1, re-injection after 3 weeks for unrelieved cases in Celestone+ lidocaine and lidocaine alone group.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-02 03:56:35 +1000" MODIFIED_BY="[Empty name]">
<P>Assessment directly after injection, 3 weeks after injection and 4 months after injection.<BR/>Definition of treatment success: asymptomatic.<BR/>Definition of treatment failure: not asymptomatic.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-11-08 11:48:39 +1100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-11-08 11:48:11 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anderson-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-08 11:48:11 +1100" MODIFIED_BY="[Empty name]">
<P>not a randomized study: prospective cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-08 11:48:16 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Benson-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-08 11:48:16 +1100" MODIFIED_BY="[Empty name]">
<P>not a randomized study: prospective cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Boyer-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>not a trial (commentary)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-08 11:48:23 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clark-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-08 11:48:23 +1100" MODIFIED_BY="[Empty name]">
<P>not a randomized study: retrospective cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-08 11:48:27 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kraemer-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-08 11:48:27 +1100" MODIFIED_BY="[Empty name]">
<P>not a randomized study: retrospective cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lopez-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>not condition of interest: tendinitis of shoulder, elbow and thumb</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maneerit-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>not comparison of interest: surgery plus steroid injection versus steroid injection alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maneerit-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>not comparison of interest: surgery plus steroid injection versus steroid injection alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McGrath-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>not a trial (review article)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-08 11:47:59 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patel-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-08 11:47:59 +1100" MODIFIED_BY="[Empty name]">
<P>not a randomized study: prospective cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-08 11:48:39 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patel-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-08 11:48:39 +1100" MODIFIED_BY="[Empty name]">
<P>not a randomized study: prospective cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Povlsen-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>not condition of interest: basal joint arthritis of the thumb</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-02 03:56:47 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stratz-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-02 03:56:47 +1000" MODIFIED_BY="[Empty name]">
<P>not condition of interest: bicipital of supraspinatus tendinitis, epicondylitis, bursitis trochanterica, pes anserinus tendinitis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Taras-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>not comparison of interest:: intra-sheath versus subcutaneous steroid injection</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2008-11-12 09:34:40 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2008-11-12 09:34:40 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal" STUDY_ID="STD-Peters-2007">
<CHAR_STUDY_NAME MODIFIED="2008-11-12 09:17:24 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<P>The Groningen Hand and Wrist Injection Therapy Trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-12 09:18:47 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<P>Randomized controlled study<BR/>Blinding of participants and outcome assessors.<BR/>Parallel groups.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-12 09:21:55 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<P>Primary care.</P>
<P>Adults.</P>
<P>Inclusion criteria: triggering or locking of a finger with or without pain and tenderness or swelling at the A1-pulley</P>
<P>Exclusion criteria: less than18 years of age, presence of an absolute contraindication for corticosteroid injection, prior treatment in the last six months with steroid injection and/ or surgery at the same anatomical location, possible traumatic or neoplastic origin of symptoms, inability to fill in follow-up forms or absence of self determination in the participant</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-12 09:24:38 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<P>Group 1: one or two injections of 1ml triamcinolonacetonide 10mg/ml</P>
<P>Group 2: one or two injections of 1ml 0,9 % NaCl</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-12 09:34:06 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<P>1. direct treatment response (consensus between physician and patient): no response; partial response, but not satisfactory, warranting further treatment; partial response, satisfactory, not warranting further treatment; complete resolution of symptoms and signs</P>
<P>2. perceived improvement (by patient): much worse, worse, not better/ not worse, better, much better</P>
<P>3.frequency of triggering: never, incidental, weekly, daily,always</P>
<P>4. pain and discomfort in the palm of the hand using a numerical rating scale: 0 = no pain to 10 = severe pain</P>
<P>5. Functional improvement using the sub items hand and finger function of the Dutch version of the second version of the Arthritis Impact Measurement Scale (DUTCH AIMS-2)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-11-12 09:25:30 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<P>2003</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-11-12 09:34:40 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<P>Cyriac Peters-Veluthamaningal, general practitioner</P>
<P>Department of General Practice</P>
<P>University Medical Center Groningen</P>
<P>Antonius Deusiglaan 1</P>
<P>9713 AV Groningen</P>
<P>the Netherlands</P>
<P> </P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-10-19 09:23:09 +1100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-10-19 09:23:09 +1100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-19 09:22:59 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lambert-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-19 09:23:09 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Murphy-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2008-08-02 18:10:44 +1000" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES MODIFIED="2008-10-29 10:35:22 +1100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-10-29 10:35:22 +1100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Methodological quality of included studies</TITLE>
<TABLE COLS="3" ROWS="11">
<TR>
<TH>
<P>Quality Item</P>
</TH>
<TH>
<P>Lambert</P>
</TH>
<TH>
<P>Murphy</P>
</TH>
</TR>
<TR>
<TD>
<P>randomization</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>concealment of allocation</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>blinding of outcome assessor</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>blinding of care provider</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>blinding of patient</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>reporting of withdrawals and dropouts</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>similarity of groups at baseline regarding most important prognostic indicators</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>unclear</P>
</TD>
</TR>
<TR>
<TD>
<P>specification of eligibility criteria</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>availability of point estimates and measures of variability of primary outcome measures</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>unclear</P>
</TD>
</TR>
<TR>
<TD>
<P>use of intention-to-treat analysis</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2008-10-29 10:35:22 +1100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE>Clinical relevance table: treatment success of steroid injection</TITLE>
<TABLE COLS="8" ROWS="5">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>n patients/ n trials</P>
</TH>
<TH>
<P>Control event rate</P>
</TH>
<TH>
<P>Wt absolute RD</P>
</TH>
<TH>
<P>Wt Rel % change</P>
</TH>
<TH>
<P>NNTB</P>
</TH>
<TH>
<P>Statistical significance</P>
</TH>
<TH>
<P>Quality of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>treatment success</P>
</TD>
<TD>
<P>63 (2)</P>
</TD>
<TD>
<P>17% 17 out of 100</P>
</TD>
<TD>
<P>38% 38 more participants out of 100</P>
</TD>
<TD>
<P>215% (I)</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>statistically significant</P>
</TD>
<TD>
<P>silver</P>
</TD>
</TR>
<TR>
<TD>
<P>95% confidence interval</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(16,59)</P>
</TD>
<TD>
<P>(34,640)</P>
</TD>
<TD>
<P>(2,18)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Legend</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Wt=weighted, RD= risk difference</P>
</TD>
<TD>
<P>Wt Rel=weighted relative percent change,<BR/>I=improvement<BR/>
</P>
</TD>
<TD>
<P>NNTB=Number needed to benefit</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-11-08 12:13:18 +1100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2008-11-08 12:13:05 +1100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Corticosteroid + lidocaine injection versus lidocaine injection &lt; 4 weeks</NAME>
<DICH_OUTCOME CHI2="0.06615649520955397" CI_END="7.404662627862267" CI_START="1.3401252423005756" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.15010718838549" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.8695052759300741" LOG_CI_START="0.12714538754267288" LOG_EFFECT_SIZE="0.4983253317363735" METHOD="MH" NO="1" P_CHI2="0.7970174024281702" P_Q="0.0" P_Z="0.008504953139499545" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="29" WEIGHT="100.0" Z="2.6313374902539866">
<NAME>treatment success</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.963917178803666" CI_START="0.9061328700366282" EFFECT_SIZE="2.85" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.9524978352620957" LOG_CI_START="-0.0428081152450753" LOG_EFFECT_SIZE="0.4548448600085102" ORDER="3991" O_E="0.0" SE="0.5846476421718264" STUDY_ID="STD-Lambert-1992" TOTAL_1="20" TOTAL_2="19" VAR="0.341812865497076" WEIGHT="55.630862657919"/>
<DICH_DATA CI_END="12.8849928957688" CI_START="0.9899192140808144" EFFECT_SIZE="3.5714285714285716" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.1100841834356812" LOG_CI_START="-0.004400246120119513" LOG_EFFECT_SIZE="0.5528419686577808" ORDER="3992" O_E="0.0" SE="0.6546536707079772" STUDY_ID="STD-Murphy-1995" TOTAL_1="14" TOTAL_2="10" VAR="0.4285714285714286" WEIGHT="44.369137342081004"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-11-08 12:13:18 +1100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Corticosteroid injection versus lidocaine injection at 4 months</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="11.789733311031693" CI_START="0.8763245427607662" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.2142857142857144" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="1.071503981273437" LOG_CI_START="-0.05733502507922586" LOG_EFFECT_SIZE="0.5070844780971057" METHOD="MH" MODIFIED="2008-08-31 06:03:47 +1000" MODIFIED_BY="Cyriac Peters-Veluthamaningal" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.07826102539565996" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="10" WEIGHT="99.99999999999999" Z="1.76086635666649">
<NAME>treatment success @ 4 months</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.789733311031693" CI_START="0.8763245427607662" EFFECT_SIZE="3.2142857142857144" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.071503981273437" LOG_CI_START="-0.05733502507922586" LOG_EFFECT_SIZE="0.5070844780971057" ORDER="3993" O_E="0.0" SE="0.6630856201747553" STUDY_ID="STD-Murphy-1995" TOTAL_1="14" TOTAL_2="10" VAR="0.4396825396825398" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-10-29 10:35:22 +1100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2008-10-29 10:35:22 +1100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>The flexor tendon sheath in the finger</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2008-10-29 10:35:22 +1100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAoAAAAIXCAIAAACDzHiPAABnxklEQVR42u29C3xcZZ3/fwpCAy7O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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-10-15 13:33:21 +1100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-10-15 13:27:00 +1100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-10-15 13:26:16 +1100" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-15 13:27:00 +1100" MODIFIED_BY="[Empty name]">
<P>1. exp fingers/<BR/>2. exp JOINTS/<BR/>3. exp Finger Joint/<BR/>4. 1 and 2<BR/>5. exp TENOSYNOVITIS/<BR/>6. exp Tendons, Para-Articular/<BR/>7. exp TENDINITIS/<BR/>8. exp Tendon Injuries/<BR/>9. exp TENDONS/de [Drug Effects]<BR/>10. trigger finger.tw.<BR/>11. trigger thumb.tw.<BR/>12. trigger digit$.tw.<BR/>13. snapping finger.tw.<BR/>14. snapping thumb.tw.<BR/>15. locking finger.tw.<BR/>16. locking thumb.tw.<BR/>17. or/1,3-16<BR/>18. exp GLUCOCORTICOIDS/<BR/>19. glucocorticoid$.tw.<BR/>20. exp Adrenal Cortex Hormones/<BR/>21. corticoster$.tw.<BR/>22. exp Methylprednisolone/<BR/>23. methylprednisolone.tw.<BR/>24. exp BETAMETHASONE/<BR/>25. betamethasone.tw.<BR/>26. exp TRIAMCINOLONE/<BR/>27. triamcinolone.tw.<BR/>28. (steroid$ adj2 inject$).tw.<BR/>29. or/18-29<BR/>30. 17 and 29<BR/>31. randomized controlled trial.pt.<BR/>32. controlled clinical trial.pt.<BR/>33. randomized controlled trials.sh.<BR/>34. random allocation.sh.<BR/>35. double blind method.sh.<BR/>36. single-blind method.sh.<BR/>37. or/31-36<BR/>38. (animal$ not human).sh.<BR/>39. 37 not 38<BR/>40. clinical trial.pt.<BR/>41. exp clinical trials/<BR/>42. (clin$ adj38 trial$).ti,ab.<BR/>43. ((singl$ or doubl$ or trebl$ or tripl$) adj38 (blind$ or mask$)).tw.<BR/>44. placebo$.sh.<BR/>45. placebo$.ti,ab.<BR/>46. random$.ti,ab.<BR/>47. research design.sh.<BR/>48. or/41-47<BR/>49. 48 not 38<BR/>50. 49 not 39<BR/>51. comparative study.sh.<BR/>52. exp evaluation studies/<BR/>53. follow up studies.sh.<BR/>54. prospective studies.sh.<BR/>55. (control$ or prospectiv$ or volunteer$).ti,ab.<BR/>56. or/51-55<BR/>57. 56 not 38<BR/>58. 57 not (39 or 50)<BR/>59. 30 and 58</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-10-15 13:28:05 +1100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-10-15 13:28:03 +1100" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-15 13:28:05 +1100" MODIFIED_BY="[Empty name]">
<P>1. exp Finger/<BR/>2. exp JOINT/<BR/>3. exp Finger Joint/<BR/>4. 1 and 2<BR/>5. exp TENOSYNOVITIS/<BR/>6. exp TENDINITIS/<BR/>7. exp Tendon Injury/<BR/>8. trigger finger.tw.<BR/>9. trigger thumb.tw.<BR/>10. trigger digit$.tw.<BR/>11. snapping finger.tw.<BR/>12. snapping thumb.tw.<BR/>13. locking finger.tw.<BR/>14. locking thumb.tw.<BR/>15. or/3-14<BR/>16. exp Glucocorticoid/<BR/>17. glucocorticoid$.tw.<BR/>18. exp Corticosteroid/<BR/>19. corticoster$.tw.<BR/>20. exp METHYLPREDNISOLONE/<BR/>21. methylprednisolone.tw.<BR/>22. exp BETAMETHASONE/<BR/>23. betamethasone.tw.<BR/>24. TRIAMCINOLONE/<BR/>25. triamcinolone.tw.<BR/>26. (steroid$ adj2 inject$).tw.<BR/>27. or/16-26<BR/>28. 15 and 27<BR/>29. random$.ti,ab.<BR/>30. factorial$.ti,ab.<BR/>31. (crossover$ or cross over$ or cross-over$).ti,ab.<BR/>32. placebo$.ti,ab.<BR/>33. (doubl$ adj blind$).ti,ab.<BR/>34. (singl$ adj blind$).ti,ab.<BR/>35. assign$.ti,ab.<BR/>36. allocat$.ti,ab.<BR/>37. volunteer$.ti,ab.<BR/>38. crossover procedure.sh.<BR/>39. double blind procedure.sh.<BR/>40. randomized controlled trial.sh.<BR/>41. single blind procedure.sh.<BR/>42. or/29-41<BR/>43. exp animal/ or nonhuman/ or exp animal experiment/<BR/>44. exp human/<BR/>45. 43 and 44<BR/>46. 43 not 45<BR/>47. 42 not 46<BR/>48. 28 and 47</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2008-10-15 13:29:14 +1100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2008-10-15 13:29:11 +1100" MODIFIED_BY="[Empty name]">CINAHL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-15 13:29:14 +1100" MODIFIED_BY="[Empty name]">
<P>1. exp fingers/<BR/>2. exp JOINTS/<BR/>3. exp Finger Joint/<BR/>4. 1 and 2<BR/>5. exp TENOSYNOVITIS/<BR/>6. exp TENDINITIS/<BR/>7. exp Tendon Injuries/<BR/>8. exp TENDONS/de [Drug Effects]<BR/>9. trigger finger.tw.<BR/>10. trigger thumb.tw.<BR/>11. trigger digit$.tw.<BR/>12. snapping finger.tw.<BR/>13. snapping thumb.tw.<BR/>14. locking finger.tw.<BR/>15. locking thumb.tw.<BR/>16. or/3-15<BR/>17. exp GLUCOCORTICOIDS/<BR/>18. glucocorticoid$.tw.<BR/>19. exp Adrenal Cortex Hormones/<BR/>20. corticoster$.tw.<BR/>21. exp Methylprednisolone/<BR/>22. methylprednisolone.tw.<BR/>23. exp BETAMETHASONE/<BR/>24. betamethasone.tw.<BR/>25. exp TRIAMCINOLONE/<BR/>26. triamcinolone.tw.<BR/>27. (steroid$ adj2 inject$).tw.<BR/>28. or/17-27<BR/>29. 16 and 28</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2008-10-15 13:29:49 +1100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2008-10-15 13:29:47 +1100" MODIFIED_BY="[Empty name]">AMED search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-15 13:29:49 +1100" MODIFIED_BY="[Empty name]">
<P>1. exp fingers/<BR/>2. exp JOINTS/<BR/>3. exp Finger Joint/<BR/>4. 1 and 2<BR/>5. exp TENOSYNOVITIS/<BR/>6. exp Tendon Injuries/<BR/>7. trigger finger.tw.<BR/>8. trigger thumb.tw.<BR/>9. trigger digit$.tw.<BR/>10. snapping finger.tw.<BR/>11. snapping thumb.tw.<BR/>12. locking finger.tw.<BR/>13. locking thumb.tw.<BR/>14. or/3-13<BR/>15. glucocorticoid$.tw.<BR/>16. exp Adrenal Cortex Hormones/<BR/>17. corticoster$.tw.<BR/>18. methylprednisolone.tw.<BR/>19. betamethasone.tw.<BR/>20. triamcinolone.tw.<BR/>21. (steroid$ adj2 inject$).tw.<BR/>22. or/15-21<BR/>23. 14 and 22</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2008-10-15 13:30:42 +1100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2008-10-15 13:30:11 +1100" MODIFIED_BY="[Empty name]">PEDro search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-15 13:30:42 +1100" MODIFIED_BY="[Empty name]">
<P>Search 1<BR/>Tenosynovitis in Abstract or title and Body Part = hand or wrist<BR/>
<BR/>Search 2<BR/>Tendon in Abstract or title and Body Part = hand or wrist<BR/>
<BR/>Search 3<BR/>Trigger or snapping or locking in Abstract or title</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2008-10-15 13:32:03 +1100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2008-10-15 13:32:00 +1100" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-15 13:32:03 +1100" MODIFIED_BY="[Empty name]">
<P>#1MeSH descriptor Fingers explode all trees<BR/>#2MeSH descriptor Joints explode all trees<BR/>#3MeSH descriptor Finger Joint explode all trees<BR/>#4(#1 AND #2)<BR/>#5MeSH descriptor Tenosynovitis explode all trees<BR/>#6MeSH descriptor Tendinopathy explode all trees<BR/>#7MeSH descriptor Tendon Injuries explode all trees<BR/>#8MeSH descriptor Tendons explode all trees with qualifier: DE<BR/>#9trigger finger:ti,ab<BR/>#10trigger thumb:ti,ab<BR/>#11trigger digit*:ti,ab<BR/>#12snapping finger:ti,ab<BR/>#13snapping thumb:ti,ab<BR/>#14locking finger:ti,ab<BR/>#15locking thumb:ti,ab<BR/>#16(#3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15)<BR/>#17MeSH descriptor Glucocorticoids explode all trees<BR/>#18 glucocorticoid*:ti,ab<BR/>#19MeSH descriptor Adrenal Cortex Hormones explode all trees<BR/>#20corticoster*:ti,ab<BR/>#21MeSH descriptor Methylprednisolone explode all trees<BR/>#22methylprednisolone:ti,ab<BR/>#23MeSH descriptor Betamethasone explode all trees<BR/>#24betamethasone:ti,ab<BR/>#25MeSH descriptor Triamcinolone explode all trees<BR/>#26triamcinolone:ti,ab<BR/>#27(steroid* near/2 inject*):ti,ab<BR/>#28(#17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27)<BR/>#29(#16 AND #28)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2008-10-15 13:32:47 +1100" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2008-10-15 13:32:45 +1100" MODIFIED_BY="[Empty name]">DARE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-15 13:32:47 +1100" MODIFIED_BY="[Empty name]">
<P>1MeSH descriptor Fingers explode all trees<BR/>#2MeSH descriptor Joints explode all trees<BR/>#3MeSH descriptor Finger Joint explode all trees<BR/>#4(#1 AND #2)<BR/>#5MeSH descriptor Tenosynovitis explode all trees<BR/>#6MeSH descriptor Tendinopathy explode all trees<BR/>#7MeSH descriptor Tendon Injuries explode all trees<BR/>#8MeSH descriptor Tendons explode all trees with qualifier: DE<BR/>#9trigger finger:ti,ab<BR/>#10trigger thumb:ti,ab<BR/>#11trigger digit*:ti,ab<BR/>#12snapping finger:ti,ab<BR/>#13snapping thumb:ti,ab<BR/>#14locking finger:ti,ab<BR/>#15locking thumb:ti,ab<BR/>#16(#3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15)<BR/>#17MeSH descriptor Glucocorticoids explode all trees<BR/>#18 glucocorticoid*:ti,ab<BR/>#19MeSH descriptor Adrenal Cortex Hormones explode all trees<BR/>#20corticoster*:ti,ab<BR/>#21MeSH descriptor Methylprednisolone explode all trees<BR/>#22methylprednisolone:ti,ab<BR/>#23MeSH descriptor Betamethasone explode all trees<BR/>#24betamethasone:ti,ab<BR/>#25MeSH descriptor Triamcinolone explode all trees<BR/>#26triamcinolone:ti,ab<BR/>#27(steroid* near/2 inject*):ti,ab<BR/>#28(#17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27)<BR/>#29(#16 AND #28)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-08" MODIFIED="2008-10-15 13:33:21 +1100" MODIFIED_BY="[Empty name]" NO="8">
<TITLE MODIFIED="2008-10-15 13:33:17 +1100" MODIFIED_BY="[Empty name]">Dissertation abstracts search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-15 13:33:21 +1100" MODIFIED_BY="[Empty name]">
<P>Search 1<BR/>Trigger finger OR trigger thumb OR trigger digit* OR locking finger OR locking thumb OR locking digit*<BR/>
<BR/>Search 2<BR/>(Tenosynovitis OR tendon*) AND (finger OR thumb OR digit*) AND (glucocorticoid* OR corticoster*) in citation or abstract</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>